mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response ind...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Xue, Gongda, Kohler, Reto, Tang, Fengyuan, Hynx, Debby, Wang, Yuhua, Orso, Francesca, Prêtre, Vincent, Ritschard, Reto, Hirschmann, Petra, Cron, Peter, Roloff, Tim, Dummer, Reinhard, Mandalà, Mario, Bichet, Sandrine, Genoud, Christel, Meyer, Alexandra G., Muraro, Manuele G., Spagnoli, Giulio C., Taverna, Daniela, Rüegg, Curzio, Merghoub, Taha, Massi, Daniela, Tang, Huifang, Levesque, Mitchell P., Dirnhofer, Stephan, Zippelius, Alfred, Hemmings, Brian A., Wicki, Andreas
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2017
主題:
Priority Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642473/
https://ncbi.nlm.nih.gov/pubmed/29050198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18213
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料